Reference : Proteomics for prediction and characterization of response to infliximab in Crohn's dise...
Scientific journals : Article
Human health sciences : Gastroenterology & hepatology
http://hdl.handle.net/2268/4955
Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study.
English
Meuwis, Marie-Alice mailto [Université de Liège - ULg > > GIGA-Management : Plate-forme protéomique >]
Fillet, Marianne mailto [Université de Liège - ULg > Département de pharmacie > Analyse des médicaments >]
Lutteri, Laurence mailto [Centre Hospitalier Universitaire de Liège - CHU > > Chimie médicale >]
Marée, Raphaël mailto [Université de Liège - ULg > > GIGA-Management : Plateforme bioinformatique >]
Geurts, Pierre mailto [Université de Liège - ULg > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Systèmes et modélisation >]
De Seny, Dominique mailto [Centre Hospitalier Universitaire de Liège - CHU > > Rhumatologie >]
Malaise, Michel mailto [Université de Liège - ULg > Département des sciences cliniques > Rhumatologie >]
Chapelle, Jean-Paul mailto [Université de Liège - ULg > Département de pharmacie > Chimie médicale >]
Wehenkel, Louis mailto [Université de Liège - ULg > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Systèmes et modélisation >]
Belaiche, Jacques mailto [Université de Liège - ULg > Département des sciences cliniques > Hépato-gastroentérologie >]
Merville, Marie-Paule mailto [Université de Liège - ULg > Département de pharmacie > Chimie médicale >]
Louis, Edouard mailto [Université de Liège - ULg > Département des sciences cliniques > Hépato-gastroentérologie - Relations académiques et scientifiques (Médecine) >]
2008
Clinical Biochemistry
Elsevier Science
41
12
960-7
Yes (verified by ORBi)
International
0009-9120
1873-2933
Tarrytown
NY
[en] Adult ; Analysis of Variance ; Anti-Inflammatory Agents/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Biological Markers/blood ; CD40 Ligand/blood ; Crohn Disease/blood/drug therapy ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Interleukin-6/blood ; Male ; Middle Aged ; Multivariate Analysis ; Pilot Projects ; Platelet Factor 4/blood ; Prognosis ; Proteomics ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
[en] OBJECTIVES: Infliximab is the first anti-TNFalpha accepted by the Food and Drug Administration for use in inflammatory bowel disease treatment. Few clinical, biological and genetic factors tend to predict response in Crohn's disease (CD) patient subcategories, none widely predicting response to infliximab. DESIGN AND METHODS: Twenty CD patients showing clinical response or non response to infliximab were used for serum proteomic profiling on Surface Enhanced Lazer Desorption Ionisation-Time of Flight-Mass Spectrometry (SELDI-TOF-MS), each before and after treatment. Univariate and multivariate data analysis were performed for prediction and characterization of response to infliximab. RESULTS: We obtained a model of classification predicting response to treatment and selected relevant potential biomarkers, among which platelet aggregation factor 4 (PF4). We quantified PF4, sCD40L and IL-6 by ELISA for correlation studies. CONCLUSIONS: This first proteomic pilot study on response to infliximab in CD suggests association between platelet metabolism and response to infliximab and requires validation studies on a larger cohort of patients.
http://hdl.handle.net/2268/4955
also: http://hdl.handle.net/2268/16473
10.1016/j.clinbiochem.2008.04.021

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Proteomics for prediction and characterization... 2008-Clin Biochem.pdfNo commentaryAuthor postprint515.22 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.